Pfizer CentreOne

Kalamazoo, MI · McPherson, KS
Biologics mRNA
361 confirmed programs · 115 sponsors · Last scored 2026-03-15
73.0
Signal Score
✓ FDA Inspections (4) ✓ Clinical Trials (361) ○ SEC Filings ○ Press

Quick Facts: Pfizer CentreOne

Signal Score
73.0/100 (as of 2026-03-15)
Quality Compliance
Assessment pending
Headquarters
Kalamazoo, MI · McPherson, KS
Modalities
Biologics, mRNA
Active CGT Programs
361 confirmed from ClinicalTrials.gov across 115 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CGT manufacturing intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA Inspections4 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2025-12-16)
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs 361
Sponsors115
ModalitiesBiologics, mRNA
361 active programs across 115 sponsors
Modalities: Biologics, mRNA
208 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT06507904 A Study to Learn How Different Preparations of Osivelotor... PHASE1 Not Yet Recruiting
NCT07227415 A Study to Learn About the Medicine Called PF-08634404 Dosed... PHASE1/PHASE2 Recruiting
NCT07123090 A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic... PHASE2 Not Yet Recruiting
NCT07222566 A Study to Learn About the Study Medicine Called PF-08634404... PHASE3 Recruiting
NCT07226999 A Study to Learn About the Study Medicine Called PF-08634404... PHASE2/PHASE3 Recruiting
NCT07261371 A Study to Compare Blood Levels of Different Dosage... PHASE1 Recruiting
NCT06974786 Frontline T-cell Engager vs Autologous Stem Cell Transplant... PHASE2 Recruiting
NCT06758401 This is a Study to Learn About How the Combination of the... PHASE3 Recruiting
NCT06918002 Elranatamab/Lenalidomide Consolidation and/or Elranatamab... PHASE3 Recruiting
NCT06987734 Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant... PHASE2 Recruiting
View all 361 programs →
Source: ClinicalTrials.gov · Retrieved Mar 20, 2026
Financial Stability 83.0
Publicly traded — financial transparency
Source: SEC EDGAR, press monitoring
Subsidiary of Pfizer
SEC FilingsParent: Pfizer
Publicly traded — financial transparency
Capacity 63.0
2 CGT manufacturing sites
Sites: Kalamazoo, MI, McPherson, KS
Source: SEC EDGAR, press monitoring, company profiles
2 CGT manufacturing sites
2 CGT manufacturing sites

FDA Inspection History

2025-12
2025-10
2025-08
2025-06
NAI VAI OAI
Date Site Type Observations Classification
2025-12-16 Pleasant Prairie, Wisconsin Drug Quality Assurance No No Action Indicated (NAI)
2025-10-24 Groton, Connecticut Bioresearch Monitoring No Voluntary Action Indicated (VAI)
2025-08-22 San Diego, California Bioresearch Monitoring No No Action Indicated (NAI)
2025-06-18 Parsippany, New Jersey Bioresearch Monitoring No No Action Indicated (NAI)
Source: FDA Data Dashboard · Retrieved Mar 20, 2026

Clinical Activity 361 studies

NCT06507904 A Study to Learn How Different Preparations of Osivelotor Taste and Enter... PHASE1 Not Yet Recruiting NCT07227415 A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in... PHASE1/PHASE2 Recruiting NCT07123090 A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma PHASE2 Not Yet Recruiting NCT07222566 A Study to Learn About the Study Medicine Called PF-08634404 in Combination... PHASE3 Recruiting NCT07226999 A Study to Learn About the Study Medicine Called PF-08634404 in Combination... PHASE2/PHASE3 Recruiting NCT07261371 A Study to Compare Blood Levels of Different Dosage Formulations of the... PHASE1 Recruiting NCT06974786 Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and... PHASE2 Recruiting NCT06758401 This is a Study to Learn About How the Combination of the Study Medicines... PHASE3 Recruiting NCT06918002 Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus... PHASE3 Recruiting NCT06987734 Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for... PHASE2 Recruiting NCT06634836 Patient Interview Study to Explore the Impact of Gene Therapy in Hemophilia A & B NA Withdrawn NCT06218069 Immuno-pet IMaging ResPonses AdministeRed Immune CheckpoiNt InhibiTor PHASE2/PHASE3 Not Yet Recruiting NCT06799026 A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma... PHASE1 Recruiting NCT06533748 Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute... PHASE2 Recruiting NCT06483100 Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance PHASE2 Recruiting NCT06704724 A Study to Learn About the Study Medicine PF-07985045 When Given Alone or... PHASE1 Active Not Recruiting NCT06075615 A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung... NA Withdrawn NCT06546553 A Study to Learn About How Different Amounts of the Study Medicine... PHASE1 Terminated NCT06207799 Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy... PHASE2 Recruiting NCT06321510 A Study to Learn About Dacomitinib in Patients With Non-small Cell Lung Cancer. NA Active Not Recruiting
+ 341 more studies
Source: ClinicalTrials.gov · Retrieved Mar 20, 2026
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Biologics CDMOs → mRNA CDMOs →